MaxCyte, Inc. Stock price

Equities

MXCT

US57777K1060

Advanced Medical Equipment & Technology

Delayed London S.E. 12:35:11 2024-03-28 pm EDT 5-day change 1st Jan Change
342.5 GBX -0.72% Intraday chart for MaxCyte, Inc. -2.84% -2.84%
Sales 2024 * 34.23M Sales 2025 * 45.52M Capitalization 451M
Net income 2024 * -51M Net income 2025 * -45M EV / Sales 2024 * 8.12 x
Net cash position 2024 * 173M Net cash position 2025 * 143M EV / Sales 2025 * 6.77 x
P/E ratio 2024 *
-8.71 x
P/E ratio 2025 *
-10.4 x
Employees 143
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.76%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.72%
1 week-2.84%
Current month-5.52%
1 month-5.52%
3 months-2.84%
6 months+37.00%
Current year-2.84%
More quotes
1 week
240.00
Extreme 240
355.00
1 month
240.00
Extreme 240
380.00
Current year
240.00
Extreme 240
430.00
1 year
170.00
Extreme 170
440.00
3 years
170.00
Extreme 170
1 235.00
5 years
95.00
Extreme 95
1 235.00
10 years
75.00
Extreme 75
1 235.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 54 23-03-26
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 22-11-30
Director/Board Member 71 06-04-30
Director/Board Member 68 04-02-29
More insiders
Date Price Change Volume
24-03-28 342.5 -0.72% 19,524
24-03-27 345 0.00% 16,722
24-03-26 345 0.00% 25,720
24-03-25 345 -2.13% 7,184
24-03-22 352.5 0.00% 96,280

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.33 USD
Average target price
9.672 USD
Spread / Average Target
+123.38%
Consensus
  1. Stock
  2. Equities
  3. Stock MaxCyte, Inc. - London S.E.